Concorde Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $237K | Buy |
+8,455
| New | +$225K | 0.12% | 169 |
|
|
2023
Q1 | – | Sell |
-4,830
| Closed | -$247K | – | 130 |
|
|
2022
Q4 | $247K | Buy |
4,830
+49
| +1% | +$2.35K | 0.22% | 109 |
|
|
2022
Q3 | $209K | Buy |
+4,781
| New | +$232K | 0.23% | 122 |
|
|
2022
Q2 | – | Sell |
-5,327
| Closed | -$276K | – | 153 |
|
|
2022
Q1 | $276K | Buy |
5,327
+978
| +22% | +$50.7K | 0.18% | 116 |
|
|
2021
Q4 | $257K | Buy |
+4,349
| New | +$215K | 0.15% | 136 |
|
|
2021
Q2 | – | Sell |
-7,477
| Closed | -$270K | – | 219 |
|
|
2021
Q1 | $270K | Sell |
7,477
-604
| -7% | -$21.4K | 0.16% | 155 |
|
|
2020
Q4 | $298K | Sell |
8,081
-622
| -7% | -$22.8K | 0.17% | 104 |
|
|
2020
Q3 | $302K | Sell |
8,703
-2,717
| -24% | -$95.3K | 0.17% | 130 |
|
|
2020
Q2 | $355K | Sell |
11,420
-260
| -2% | -$8.83K | 0.3% | 73 |
|
|
2020
Q1 | $362K | Buy |
11,680
+2,511
| +27% | +$85.6K | 0.37% | 62 |
|
|
2019
Q4 | $340K | Buy |
9,169
+378
| +4% | +$13.5K | 0.24% | 96 |
|
|
2019
Q3 | $300K | Sell |
8,791
-1,648
| -16% | -$59.9K | 0.23% | 101 |
|
|
2019
Q2 | $428K | Sell |
10,439
-508
| -5% | -$20.2K | 0.25% | 121 |
|
|
2019
Q1 | $442K | Buy |
10,947
+1,206
| +12% | +$48.3K | 0.29% | 115 |
|
|
2018
Q4 | $402K | Buy |
9,741
+2,980
| +44% | +$124K | 0.34% | 96 |
|
|
2018
Q3 | $285K | Buy |
6,761
+14
| +0.2% | +$539 | 0.28% | 97 |
|
|
2018
Q2 | $232K | Buy |
+6,747
| New | +$231K | 0.26% | 106 |
|
|
2018
Q1 | – | Sell |
-7,007
| Closed | -$242K | – | 120 |
|
|
2017
Q4 | $242K | Sell |
7,007
-3,501
| -33% | -$119K | 0.31% | 94 |
|
|
2017
Q3 | $358K | Buy |
10,508
+1,453
| +16% | +$46.7K | 0.31% | 90 |
|
|
2017
Q2 | $289K | Sell |
9,055
-8,091
| -47% | -$255K | 0.39% | 93 |
|
|
2017
Q1 | $556K | Buy |
17,146
+3,957
| +30% | +$125K | 0.92% | 26 |
|
|
2016
Q4 | $408K | Sell |
13,189
-19,716
| -60% | -$602K | 0.73% | 52 |
|
|
2016
Q3 | $1.06M | Buy |
32,905
+17,909
| +119% | +$599K | 1.33% | 20 |
|
|
2016
Q2 | $501K | Buy |
14,996
+4,735
| +46% | +$151K | 0.5% | 48 |
|
|
2016
Q1 | $288K | Buy |
10,261
+3,723
| +57% | +$106K | 0.33% | 75 |
|
|
2015
Q4 | $199K | Buy |
+6,538
| New | +$206K | 0.22% | 104 |
|
|
2015
Q3 | – | Sell |
-17,102
| Closed | -$543K | – | 116 |
|
|
2015
Q2 | $543K | Buy |
17,102
+907
| +6% | +$29.6K | 0.69% | 36 |
|
|
2015
Q1 | $534K | Sell |
16,195
-513
| -3% | -$16.3K | 0.61% | 36 |
|
|
2014
Q4 | $516K | Buy |
+16,708
| New | +$479K | 0.65% | 39 |
|
Other funds holding PFE
VCM
VPM
Concorde Asset Management's PFE Position: Q1 2026 in Review
Concorde Asset Management opened a new position in Pfizer (PFE) in Q1 2026: 8,455 shares worth $237K. The stake represents 0.12% of the portfolio and ranks #169 among its holdings. This is a return to the name: Concorde Asset Management previously reported a position in PFE as recently as Q4 2022.
Concorde Asset Management first reported a position in PFE in Q4 2014 and has held it in 29 quarters since. The position peaked at $1.06M in Q3 2016. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Concorde Asset Management held 8,455 shares of Pfizer worth $237K as of Q1 2026.
- Pfizer was a new Concorde Asset Management position in Q1 2026.
- Pfizer made up 0.12% of Concorde Asset Management's portfolio in Q1 2026, its #169 holding.
- Concorde Asset Management first reported a position in Pfizer in Q4 2014 and has held it in 29 quarters since.
- Concorde Asset Management's Pfizer position peaked at $1.06M in Q3 2016.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Concorde Asset Management's 13F filing for Q1 2026, filed 1 Jun 2026.